Performs laboratory tests for physicians, including CyPath Lung, a noninvasive test that helps assess patients for early-stage lung cancer.
10-K for FY2025, filed Mar 16, 2026We develop noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry…View ↗
CyPath® Lung addresses the need for noninvasive detection of early-stage lung cancer with the proven ability to detect the leading cancer…View ↗
CyPath® Lung is performed and offered by our wholly owned subsidiary PPLS, a clinical anatomic and pathology laboratory which we acquired…View ↗
The lab brings in fees for patient tests when results are reported, and for histology and medical-director services when those services are performed.
10-K for FY2025, filed Mar 16, 2026Post-acquisition of PPLS, additional revenue streams have been consolidated since September 19, 2023. PPLS generates three sources of…View ↗
10-K for FY2025, filed Mar 16, 2026
FY2025 revenue by product or service ↗$6.2M
10-K for FY2025, filed Mar 16, 2026
$6.2M ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Health Care, Patient Service
Sold outright
10-K for FY2025, filed Mar 16, 2026 |
81% |
Health Care, Patient Service, FY2025
$5M Sources
|
Sold outright |
|
Histology Service Fees
Sold outright
10-K for FY2025, filed Mar 16, 2026 |
18% |
Histology Service Fees, FY2025
$1.1M Sources
|
Sold outright |
|
Medical Director Fees
Sold outright
|
1.1% |
Medical Director Fees, FY2025
$68.3K Sources
|
Sold outright |
|
Department of Defense Observational Studies
|
<0.1% |
Department of Defense Observational Studies, FY2025
$577 Sources
|
|
|
Other Revenues
|
0.1%
FY2022: 100%
|
Other Revenues, FY2025
$4.9K Sources
|
Physicians order CyPath Lung for patients being evaluated for lung cancer; PPLS offers the test to physicians and operates a commercial pathology laboratory.
10-K for FY2025, filed Mar 16, 2026
No. It lost $14.9M in FY2025.
10-Q for Q3 FY2026, filed Nov 6, 2026
−$5.3MView ↗
10-Q for Q3 FY2026, filed Nov 6, 2026
Open tableView ↗
8-K, filed Sep 9, 2026
On September 8, 2026, the Company received written notice (the “Written Notice”) from the Staff confirming that the Company has regained…View ↗
8-K, filed Aug 18, 2026
On August 18, 2026, bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), issued a press release announcing that it has…View ↗
Shrinking. Revenue fell 11% in 3 years, from $6.9M in FY2022 to $6.2M in FY2025, about 4% a year.
Ownership of the pathology lab
The earlier report described Precision Pathology as developing and performing CyPath Lung under a joint agreement; the latest report says bioAffinity owns and operates the commercial laboratory.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 16, 2026Following completion of the test validation trial, CyPath® Lung was evaluated independently by Precision Pathology, which developed the…View ↗
Commercial laboratory services, including CyPath® Lung, are performed at our wholly owned subsidiary PPLS which we acquired by purchasing…View ↗
A more focused cancer-treatment effort
The earlier report described broader cancer-therapy research; the latest report describes continued research toward topical treatment for squamous cell skin cancer.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 16, 2026Through our wholly owned subsidiary, OncoSelect® Therapeutics, LLC, our research has led to discoveries and advancement of novel cancer…View ↗
Through our wholly owned subsidiary, OncoSelect® Therapeutics, LLC, we have conducted research that has led to discoveries and advancement…View ↗
Competes with LungLife AI, Biodesix, and Veracyte
10-K for FY2025, filed Mar 16, 2026A balanced test called LungLB (sold by LungLife AI in the US) is commercially available as a laboratory developed test and has an insurance…View ↗
Loading...